Nasdaq · CIK 0001802369
ADRX ADARx Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $17.78 on Oct 9, 2026, +3% from the 52-week low and -14% from the high.
Last 90 days
Net insider value
+$88M
more bought than sold
Buys
5
$88M by 5 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
ADRXOct 9, 2026 · close 17.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ADARx Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Orbimed Advisors LLC director, owner buy | $16M 950,000 shares | +7% | - | |
| 58Moderate | Carl L Gordon director, owner buy | $16M 950,000 shares | +7% | - | |
| 50Moderate | Erez Chimovits director buy | $1.0M 61,516 shares | +1% | - | |
| 61Notable | Simeon George director, owner buy | $27M 1,600,000 shares | +32% | - | |
| 53Moderate | Sr One Capital Management, LLC owner buy | $27M 1,600,000 shares | +32% | - |
Transactions
The last 94 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +300,249 | $17.00 | $5.1M | 14,325,529 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +300,249 | $17.00 | $5.1M | 14,325,529 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 11 d ago |
| Sep 28, 2026 | Erez Chimovits director | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +588,235 | $17.00 | $10.0M | 588,235 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +588,235 | $17.00 | $10.0M | 588,235 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Orbimed Advisors LLC director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | Carl L Gordon director, owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +8,908,775 | - | - | 8,908,775 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Common Stockindirect: See Note 2 | +3,334,938 | - | - | 3,334,938 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Common Stockindirect: See Note 2 | +3,334,938 | - | - | 3,334,938 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Common Stockindirect: See Note 2 | +1,113,666 | - | - | 4,448,604 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Common Stockindirect: See Note 2 | +1,113,666 | - | - | 4,448,604 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +1,667,469 | - | - | 10,576,244 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Common Stockindirect: See Note 2 | +512,897 | - | - | 4,961,501 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Common Stockindirect: See Note 2 | +512,897 | - | - | 4,961,501 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +513,067 | - | - | 11,089,311 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Note 2 | +592,593 | $17.00 | $10M | 5,554,094 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Common Stock | +153,868 | - | - | 11,243,179 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | POpen-market purchase Common Stockindirect: See Note 2 | +592,593 | $17.00 | $10M | 5,554,094 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Common Stockindirect: See Note 3 | +1,538,691 | - | - | 1,538,691 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Common Stockindirect: By LAV Fund VI, L.P. | +307,738 | - | - | 307,738 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Common Stockindirect: See Note 3 | +1,538,691 | - | - | 1,538,691 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Common Stockindirect: By LAV Fund VI Opportunities, L.P. | +307,738 | - | - | 307,738 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | POpen-market purchase Common Stockindirect: See Note 3 | +414,814 | $17.00 | $7.1M | 1,953,505 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Note 3 | +414,814 | $17.00 | $7.1M | 1,953,505 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Common Stockindirect: See Note 4 | +1,667,468 | - | - | 1,667,468 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Common Stockindirect: See Note 4 | +1,667,468 | - | - | 1,667,468 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Series A Preferred Stockderivative | -10,438,412 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Common Stockindirect: See Note 4 | +169,001 | - | - | 1,836,469 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Common Stockindirect: See Note 4 | +169,001 | - | - | 1,836,469 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Series B Preferred Stockderivative | -1,953,774 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Note 5 | +592,593 | $17.00 | $10M | 592,593 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Series B-1 Preferred Stockderivative | -601,161 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | POpen-market purchase Common Stockindirect: See Note 5 | +592,593 | $17.00 | $10M | 592,593 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Series B Preferred Stockderivativeindirect: See Note 2 | -3,907,547 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Series C Preferred Stockderivative | -180,288 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Series B Preferred Stockderivativeindirect: See Note 2 | -3,907,547 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Series C Preferred Stockderivativeindirect: By LAV Fund VI, L.P. | -360,577 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See Note 2 | -1,304,883 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Series B-1 Preferred Stockderivativeindirect: See Note 2 | -1,304,883 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Series C Preferred Stockderivativeindirect: See Note 2 | -600,962 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Series C Preferred Stockderivativeindirect: See Note 2 | -600,962 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | LAV Biosciences Fund V, L.P. owner | CConversion Series C Preferred Stockderivativeindirect: By LAV Fund VI Opportunities, L.P. | -360,577 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Series C Preferred Stockderivativeindirect: See Note 3 | -1,802,885 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Series C Preferred Stockderivativeindirect: See Note 3 | -1,802,885 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Series B Preferred Stockderivativeindirect: See Note 4 | -1,953,773 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Series B Preferred Stockderivativeindirect: See Note 4 | -1,953,773 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Simeon George director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: See Note 4 | -198,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | Sr One Capital Management, LLC owner | CConversion Series B-1 Preferred Stockderivativeindirect: See Note 4 | -198,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 24, 2026 | Zhen Li President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +1,024,152 | $0.00 | $0 | 1,024,152 | 13 d ago |
| Sep 24, 2026 | Ryan Fisk CFO and CBO | AGrant or award Employee Stock Option (right to buy)derivative | +170,692 | $0.00 | $0 | 170,692 | 13 d ago |
| Sep 24, 2026 | Robert William Ackles Chief People Officer | AGrant or award Employee Stock Option (right to buy)derivative | +85,346 | $0.00 | $0 | 85,346 | 13 d ago |
| Sep 24, 2026 | Rui (NMN) Zhu Chief Technology Officer | AGrant or award Employee Stock Option (right to buy)derivative | +512,076 | $0.00 | $0 | 512,076 | 13 d ago |
| Sep 24, 2026 | Alan Robert MacLeod Chief Scientific Officer | AGrant or award Employee Stock Option (right to buy)derivative | +170,692 | $0.00 | $0 | 170,692 | 13 d ago |
Insiders
Everyone who has filed a Form 4 here.
- Robert William AcklesChief People Officer
- Erez Chimovitsdirector, owner
- Ryan FiskCFO and CBO
- Carl L Gordondirector, owner
- Simeon Georgedirector, owner
- LAV Biosciences Fund V, L.P.owner
- Zhen LiPresident and CEO
- Alan Robert MacLeodChief Scientific Officer
- Orbimed Advisors LLCdirector, owner
- Sr One Capital Management, LLCowner
- Rui (NMN) ZhuChief Technology Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.